Citi Research issued a research report lowering its FY2026/ FY2027 revenue forecasts for ALI HEALTH (00241.HK) -0.020 (-0.442%) Short selling $262.31M; Ratio 40.865% by 3%/ 6%, and reducing its EPS forecasts by 23%/ 19%, reflecting a slowdown in revenue growth and a decline in gross profit margin due to increased prescription drug sales. Therefore, the broker dropped its target price from $9.5 to $8.5, with rating at Buy.ALI HEALTH's management is guiding for a FY2026 revenue growth of 5-10% YoY, with an adjusted net profit growth guidance of 10-20%, Citi Research added. Meanwhile, ALI HEALTH will closely monitor the market share of its major competitors and dynamically adjust its cost and resource allocation amid fierce competition.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-23 16:25.)Related NewsCICC Raises ALI HEALTH (00241.HK) TP by 17% to $5.5 as Results Largely in Line